Search Results
Showing Results for ritonavir
Dr. Jon Salmanton-GarcÃa discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.
We are excited to introduce the latest edition of touchREVIEWS in Infectious Diseases. Our mission is to bring you thought-provoking interviews, reviews, editorials, case studies and original research within the realm of infectious diseases. We aspire to engage infectious disease ...
The treatment of people with HIV (PWH)/hepatitis B virus (HBV) co-infection, especially those who have additional comorbidities requiring multiple drug therapies can be problematic. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a co-formulated medication consisting of two components ...
Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal ...
Molnupiravir is an oral antiviral medication that has shown to be effective in treating COVID-19. Nirmatrelvir/ritonavir is a combination of two drugs that have been granted emergency use authorization for the treatment of COVID-19. Dr Jon Salmanton-Garcia (University of ...
The MONET phase 3 study investigated the safety and efficacy of several monoclonal antibodies (sotrovimab tixagevimab/cilgavimab, and nirmatrelvir–ritonavir) for the treatment of COVID-19 in non-hospitalised adult patients. We caught up with Dr. Valentina Mazzotta (IRCCS, Rome, Italy) to discuss ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
